Trials / Completed
CompletedNCT04051307
Dual Vaccine Trial in Myeloproliferative Neoplasms
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Inge Marie Svane · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1 peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to vaccination and subsequently safety, toxicity and clinical effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL | Peptide vaccination |
| DRUG | Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL | Peptide vaccination |
Timeline
- Start date
- 2019-07-10
- Primary completion
- 2022-07-10
- Completion
- 2022-07-10
- First posted
- 2019-08-09
- Last updated
- 2023-07-13
Locations
2 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04051307. Inclusion in this directory is not an endorsement.